SOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company has a partnership with Synnovis to bring blood-based cancer testing to patients in the United Kingdom and a collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies. The company was incorporated in 2011 and is based in Rolle, Switzerland.
- Symbol
- SOPH
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $543.28M
- 52 week range
- 3.37 - 8.98
Valuation
- Share price
- $8.08 (close of 2026-09-23)
- P/E (TTM)
- -6.30x
- Price to book
- 7.08x
- Price to free cash flow
- -4.99x
- Enterprise value
- $512.27M
- Book value per share
- $1.14
Price performance
| Period | Change |
|---|
| 1 day | -1.94% |
| 5 days | +1.51% |
| 1 month | -6.59% |
| 3 months | +54.49% |
| 6 months | +55.68% |
| Year to date | +73.02% |
| 1 year | +104.04% |
| 3 years | +239.50% |
| 5 years | -53.48% |
| All time | -51.79% |
Profitability and growth
- Return on equity
- -167.57%
- Return on invested capital
- -177.82%
- Return on assets
- -48.46%
- Return on capital employed
- -63.03%
- Gross margin
- 67.40%
- Net margin
- -102.24%
- EBITDA margin
- -86.62%
- Revenue growth
- 18.56%
- Net income growth
- -26.41%
- Free cash flow growth
- 18.53%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -20.03%
- Current ratio
- 3.39x
- Net debt to EBITDA
- 0.40x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $77.27M
- Cost of revenue
- $25.19M
- Gross profit
- $52.08M
- EBITDA
- $-66.93M
- Net income
- $-79.00M
- Earnings per share
- $-1.17
- Research and development
- $34.22M
- Shares outstanding
- 67.54M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $77.27M | $52.08M | $-79.00M | $-1.17 |
| 2024-12-31 | $65.17M | $43.94M | $-62.49M | $-0.95 |
| 2023-12-31 | $62.37M | $42.91M | $-78.98M | $-1.22 |
| 2022-12-31 | $47.56M | $31.25M | $-87.45M | $-1.36 |
| 2021-12-31 | $40.45M | $25.22M | $-73.67M | $-1.33 |
| 2020-12-31 | $28.40M | $17.69M | $-39.34M | $-0.93 |
| 2019-12-31 | $25.36M | $17.83M | $-33.79M | $0.00 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 67.40% | -102.24% | -167.57% | -177.82% |
| 2024-12-31 | 67.42% | -95.89% | -64.77% | -143.79% |
| 2023-12-31 | 68.80% | -126.63% | -52.15% | -159.91% |
| 2022-12-31 | 65.71% | -183.87% | -43.70% | -157.80% |
| 2021-12-31 | 62.35% | -182.14% | -26.75% | -74.86% |
| 2020-12-31 | 62.29% | -138.52% | -39.14% | -107.14% |
| 2019-12-31 | 70.30% | -133.23% | -151.85% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $70.29M | $47.73M |
| 2024-12-31 | $80.23M | $13.24M |
| 2023-12-31 | $123.25M | - |
| 2022-12-31 | $161.31M | - |
| 2021-12-31 | $192.96M | - |
| 2020-12-31 | $74.63M | $457.00K |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-36.47M | $16.20M |
| 2024-12-31 | $-44.76M | $16.49M |
| 2023-12-31 | $-54.72M | $15.24M |
| 2022-12-31 | $-74.19M | $13.61M |
| 2021-12-31 | $-60.62M | $8.51M |
| 2020-12-31 | $-32.18M | $1.36M |
| 2019-12-31 | $-33.03M | $717.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-04 | Jun/2026 | - |
| 2026-05-05 | - | - |
| 2026-03-03 | - | - |
| 2025-11-04 | - | - |
| 2025-08-05 | - | - |
| 2025-05-06 | - | - |
| 2025-03-04 | - | - |
| 2024-11-05 | - | - |
Filings and sources
- Company website
- sophiagenetics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades